<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-126612</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Primary hyperoxaluria</dc:title>
<dc:description xml:lang="en">Primary hyperoxaluria (PH) occurs due to an autosomal recessive hereditary disorder of the metabolism of glyoxylate, which causes excessive oxalate production. The most frequent and serious disorder is due to enzyme deficit of alanine-glyoxylate aminotransferase (PH type I) specific to hepatic peroxisome. As oxalate is not metabolised in humans and is excreted through the kidneys, the kidney is the first organ affected, causing recurrent lithiasis, nephrocalcinosis and early renal failure. With advance of renal failure, particularly in patients on haemodialysis (HD), calcium oxalate is massively deposited in tissues, which is known as oxalosis. Diagnosis is based on family history, the presence of urolithiasis and/or nephrocalcinosis, hyperoxaluria, oxalate deposits in tissue forming granulomas, molecular analysis of DNA and enzyme analysis if applicable. High diagnostic suspicion is required; therefore, unfortunately, in many cases it is diagnosed after its recurrence following kidney transplantation. Conservative management of this disease (high liquid intake, pyridoxine and crystallisation inhibitors) needs to be adopted early in order to delay kidney damage. Treatment by dialysis is ineffective in  (..) (AU)</dc:description>
<dc:creator>Salido, Eduardo</dc:creator>
<dc:creator>Lorenzo, Víctor</dc:creator>
<dc:creator>Torres, Armando</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La hiperoxaluria primaria (HOP) se debe a un desorden metabólico hereditario autosómico recesivo, del metabolismo del glioxalato, que causa una producción excesiva de oxalato. El trastorno más frecuente y grave se debe al déficit enzimático de alanin: glioxalato aminotransferasa (HOP tipo I) específico en el peroxisoma hepático. Dado que el oxalato no se metaboliza en los humanos y se elimina por vía renal, el riñón es el primer órgano afectado, dando lugar a la aparición de litiasis de repetición, nefrocalcinosis e insuficiencia renal precoz. Con la progresión de la insuficiencia renal, especialmente en pacientes sometidos a hemodiálisis (HD), el oxalato cálcico se deposita masivamente en los tejidos, denominándose a esto último oxalosis. El diagnóstico se basa en los antecedentes familiares, la presencia de urolitiasis y/o nefrocalcinosis, hiperoxaluria, depósitos tisulares de oxalato formando granulomas en formas avanzadas, análisis molecular de ADN y análisis enzimático si procede. Se requiere una alta sospecha diagnóstica, por lo que, desafortunadamente, en muchos casos se diagnostica tras su recidiva en el trasplante (..) (AU)</dc:description>
<dc:source>Nefrologia;34(3): 398-412, mayo-jun. 2014. ilus, tab</dc:source>
<dc:identifier>ibc-126612</dc:identifier>
<dc:title xml:lang="es">Hiperoxaluria primaria</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d52124^s22032</dc:subject>
<dc:subject>^d9590^s22032</dc:subject>
<dc:subject>^d50495^s22032</dc:subject>
<dc:subject>^d29476^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29475^s22074</dc:subject>
<dc:subject>^d19194^s22032</dc:subject>
<dc:subject>^d6182^s22044</dc:subject>
<dc:type>article</dc:type>
<dc:date>201406</dc:date>
</metadata>
</record>
</ibecs-document>
